Navigation Links
Egalet Appoints Stan Musial as CFO
Date:5/8/2013

MALVERN, Pa., May 8, 2013 /PRNewswire/ -- Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today the appointment of Stan Musial as chief financial officer (CFO). 

"The addition of Stan to the management team comes at a critical time as the most advanced products in Egalet's pipeline of abuse-deterrent opioids are nearing phase 3," said Bob Radie , president and CEO.  "Stan's finance experience will be invaluable as we move our pipeline through development and ultimately to the commercial market."

Stan has held senior financial management positions for both publicly-held and privately-held companies, becoming experienced in executing growth strategies, raising capital, and mergers and acquisitions.  Stan most recently spent six years as vice president of finance and administration, chief financial officer, treasurer and secretary of Prism Pharmaceuticals, a specialty pharmaceutical company, which was successfully sold to Baxter Healthcare in 2011.  Prior to joining Prism he held the position of vice president, finance, and CFO for Strategic Diagnostics, Inc. (SDIX), a publicly-held biotechnology company.  He began his career with KPMG LLP.  Stan holds an MBA in finance from Temple University and a B.S. degree in accounting from Pennsylvania State University and is a Certified Public Accountant.

"I am excited to join Egalet—a company seeking to advance its pipeline of abuse deterrent opioids by taking advantage of the expedited 505(b)(2) regulatory pathway to address the growing need for safe pain medicines," said Stan Musial

About Egalet Ltd.
Egalet Ltd. is a European-based specialty pharmaceutical company using its patented technology to produce novel therapeutics on its own and with partners.  Based on the proprietary technology, Egalet is developing a pipeline of abuse-deterrent opioids that are nearing pivotal testing.  In addition, Egalet has collaborations with pharmaceutical and biotechnology companies in the initial phase of clinical testing. 

Egalet has pioneered one of the world's first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet.   In addition, the Egalet® technology, a novel, patented drug delivery platform, is designed to prevent easy extraction and to deter the abuse of medications via known routes of abuse, including chewing, snorting, and injecting.  The uniquely shaped, patient-friendly tablet consists of matrix and can add a shell or coat.  By altering the composition of the shell and matrix, a variety of extended-release formulations can be produced.  The technology offers a predictable and tailored pharmacokinetic profile, lacks a significant food effect and alcohol dose dumping, and can be used with a broad range of opioids and non-opioids.  Egalet has an extensive portfolio of both filed patents and patent applications to protect its inventions covering both the platform technology and specific products.  Please visit www.egalet.com for more information.

Contact:
E. Blair Schoeb 
Tel.: 917-432-9275
Email: blair@biotechcomm.com  


'/>"/>
SOURCE Egalet Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Egalet to Present at Life Sciences Europe Conference
2. Egalet Announces Issuance of U.S. Patent
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Elsevier Appoints New President of Elsevier CPM Resource Center
8. GenWay Biotech Appoints New Vice President of Custom/OEM
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):